Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988465 · ClinicalTrials.gov registry record
HemoSonics - UTMB Cardiac Surgery Study
A clinical trial, sponsored by HemoSonics.
- Completed
- Registry status
- 30
- Enrollment target
NCT03988465: Completed study, sponsored by HemoSonics.
NCT03988465 is a clinical trial that has completed, run by HemoSonics. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988465 has completed, sponsored by HemoSonics.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra QPlus Cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device.
Primary Outcome
Coagulation function assessed by Quantra and TEG 5000
Interventions
- DIAGNOSTIC_TEST Quantra System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-06-19 |
| Est. Completion | 2020-05-15 |
What the finished NCT03988465 record still lists
NCT03988465 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Quantra System is the first listed.
NCT03988465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03988465 about?
NCT03988465 is a clinical study titled "HemoSonics - UTMB Cardiac Surgery Study". This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra QPlus Cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device.
What is the current status of trial NCT03988465?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-06-19. Estimated completion is 2020-05-15.
What interventions are being tested in trial NCT03988465?
The interventions under investigation include: Quantra System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03988465?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI